



Euro BioFairs Compass

Summer 2015

Guide to Life Sciences **Events**



SPECIAL

Join the European Biotechnology Network!



The European Biotechnology Network is dedicated to facilitating co-operation between professionals in biotechnology and the life sciences all over Europe. This non-profit organisation brings research groups, universities, SMEs, large companies and indeed all actors in biotechnology together to build and deliver partnerships.

Do you want to know more about the advantages of a (free) membership? Just have a look at our website.



European Biotechnology Network AISBL
Rue de la Science 14b | 1040 Brussels, Belgium
Tel: +32 (0)2 733 72 37
info@european-biotechnology.net
www.european-biotechnology.net

CORPORATE MEMBERS



Where do you want to go today?

EVENT GUIDE The EuroBiotech Compass shows you which highlights to mark on your event calendar.

From partnering to scientific congresses, from product shows to technology offerings – this coming autumn will be a long series of highlights that could have an impact on your business. However, the skyrocketing number of events demand careful choices. This edition of the EURO BIOFAIRS COMPASS presents the must-attend events in the months to come. Whether you're looking for a licensing partner, need financing or just want to find out more about the latest developments in R&D equipment and services, you'll find everything you need to know about what each event provides.

Based on advanced partnering and networking tools, **Nordic Life Science Days** (see p. 62) showcases the best the Nordic region has to offer. The mix of conference, partnering and exhibition is hosted in Stockholm (9–10 September).

Spotlight on the bioeconomy

More than 200 experts are expected at this year's **Conference on Carbon Dioxide as Feedstock for Fuels, Chemistry and Polymers** (see p. 64) in Essen. The event is the largest of its kind in Europe and will illuminate the new paradigm of the CO₂ economy (29–30 September).

In mid-October, a whole week will be dedicated to communicate the benefits of biotechnology to the public. The **European Biotech Week** (see p. 66) is organised by EuropaBio, the European Association for Bioindustries, and features more than 200 events all across Europe.

Companies aiming to expand in the Far East would be well-advised to attend Asia's largest biotech event, the **BioJapan 2015** (14–16 October, see p. 68).

International cooperation and tech transfer in growing eastern European markets will be at the focus of **Bioinnovation 2015** (see p. 70), which again

takes place in Gdansk this year (19–20 October).

The biotech industry's largest partnering event, **EBD's BioEurope 2015** (2–4 November), will provide the perfect meeting point for biotechs, investors and pharma executives in Munich (see p. 72).

The biosimilars pathway

Ten years after the introduction of a regulatory pathway for biosimilars in the EU, DIA is arranging its third annual EU conference on this ever-evolving regulatory topic to keep all relevant stakeholders up to date. The **DIA Biosimilars Conference 2015** (see p. 74) will be hosted in London (4–5 November).

For the third year running, **Pharma-Lab** (see p. 76) calls upon the latest regulatory and scientific developments in all laboratory areas of the pharmaceutical industry (10–11 November). The event, to be held in Neuss, is accompanied by an exhibition, in which suppliers of lab equipment, and contract laboratories present their offerings.

Up to 400 delegates are expected to attend the **3rd International mRNA Health Conference** (see p. 78) in Berlin, a key date for everyone who is working with mRNA for medical purposes or seeking messenger RNA as a novel tool to express proteins directly *in situ* (11–12 November).

2015 is the 20th anniversary year of **euroPLX Pharma Partnering Conferences** (see p. 80). Geographically, euroPLX has been global from the onset. This time, the popular event aimed at business development executives, will take place in the Greek Capital Athens (23–24 November).

Just turn the page to learn everything you need to know about Europe's must-attend events in the biotech industry. ■



Communication and dissemination services for EU-funded consortia

Are you looking for a communications partner in Horizon 2020 and other R&D programmes? As an SME with more than 25 years of experience in biotechnology/life sciences, BIOCOM is the perfect partner for your communication and dissemination needs.



- Project branding and preparation of communications materials
- Creation, maintenance and updating of the project website
- Press and media work, incl. videos
- Organisation of conferences and workshops

Interested?

For more information, just head to www.biocom.de/comdis or contact Dr. Boris Mannhardt at b.mannhardt@biocom.de



9–10 September, 2015
Waterfront Convention Center
Stockholm, Sweden

Time for partnering

NORDIC LIFE SCIENCE DAYS The Nordic region is proud to host some of the world's most innovative biotech, medtech and pharma companies. It also has the 12th strongest economy worldwide, making it the perfect place to invest and partner.

The Nordic Life Science Days are bringing together some of the best talents in Life Sciences, offering amazing networking and partnering opportunities, providing inputs and content on the most recent trends.

Nordic Life Science Days attract leading decision makers from the Life Sciences sector, not only from biotech, pharma and medtech but also from finances, research, policy and regulatory authorities.

Based on cutting-edge and advanced partnering and networking tools, Nordic Life Science Days showcases the best the Nordic region has to offer.

Together with our co-hosts ScanBalt BioRegion, Swedish Medtech, and LIF we invite companies throughout the Nordic and the Baltic Sea regions to network, partner and showcase together in Stockholm.

Interactive layout

The 2015 conference design will feature a new exhibition layout creating more interactions with the exhibitors, an enriched programme featuring ten Super Sessions and topical workshops, an innovative company presentation format bringing more value to the presenters and the audience, new partnering areas allowing more comfort and privacy, extended informal networking opportunities.

Based on attendance at previous events, Nordic Life Science Days 2015 is expecting 900 to 1000+ international delegates. ■

About Bionordic

Welcome *Bionordic is a global event management company, organising and producing conferences and corporate events. It supports a*



large range of international clients including public and private agencies, non-governmental organisations, regional and multinational corporations.

We are part of the new Life Sciences ecosystem, being innovative, creating content and value for our customers. We conceive, produce and deliver unique events and substantial partnering and networking opportunities.

Based on cutting edge and technology solutions, we offer our clients a full in-house specialist event management service supported by a passionate team of experts focused on creating amazing events. We are proud to be the official producer of the Nordic Life Science Days, a SwedenBIO event that is the largest Nordic partnering conference for the global Life Sciences industry.

In 2015, we welcome ScanBalt BioRegion, Swedish Medtech and LIF, the research-based pharmaceutical industry organisation, as special co-hosts.

Olivier Duchamp
Managing Director, NLS Days
Chairman and CEO
Bionordic Services

› QUICK FACTS

2014 Highlights

- › 890 participants
- › 28 countries
- › 7,700 meeting requests
- › 1,600 scheduled meetings
- › 490 licensing opportunities

Registration and Information

www.nlsdays.com
olivier.duchamp@bionordic.org
Phone +33 608 804 515

NLSDAYS 2015

Nordic Life Science Days

September 9-10, 2015
Stockholm, Sweden

Nordic Life Science Days is a The Swedish Life Science Industry Organization **sweden BIO** event

Produced by **bionordic**

Invest - Partner - Network

2 days for meeting with the best the Nordic region has to offer
2 days for new partnering opportunities
2 days for entering into new deals



Register now at
www.nlsdays.com

Special NLSDays 2015 Co-Hosts:

Official Media Partner:

Partnering powered by:





29–30 September, 2015
Haus der Technik
Essen, Germany

Value from waste

4TH CONFERENCE ON CO₂ How to cover the demand for fuels and chemicals in 2050? For the fourth year in a row, the Conference on Carbon Dioxide as Feedstock for Fuels, Chemistry and Polymers will discuss Carbon Capture and Utilisation's (CCU) possible breakthrough as future market driver. More than 200 experts are expected at this year's largest CCU event in Europe.

The explosion of interest in CO₂ has led to a new awareness at industrial, societal and scientific levels with the result that CO₂ is no longer a mere waste product, but rather an abundant, low cost raw material. Using carbon dioxide as feedstock for fuels, chemistry and polymers is a big challenge and chance for our sustainable future and has immense potential for the coming decade – much faster than expected!

This year's conference focus is on energy production from carbon dioxide. High on the European research agenda, scientists are very active in CCU research, especially in the fields of solar fuels (power-to-fuel, power-to-gas) – but also in CO₂-based chemicals and polymers. Leading companies will showcase new and enhanced applications using carbon dioxide as feedstock. Representatives from political bodies and research institutes will be

on hand at the event to present and discuss the latest national and regional policies, strategies and visions.

Currently a range of problems still need to be solved: efficiency, cost and political support are on top of the agenda. Significant progress has recently been made in terms of efficiency and cost; artificial photosynthesis has already reached the efficiency of plants and strives to be thirty times higher. The nova conference will showcase the latest developments from the US, which is – along with Germany – the worldwide leading nation in CCU technologies. Political support is only just beginning to form. Brussels plans to equate CO₂-based fuels with fuels made of biomass in the near future, which would constitute an important step towards recognition and progress. Delegates from the European Commission will present the current status of reform and will discuss future prospects for developments after 2020. ■

Taking part

GREETING *It sounds like a daring vision – but could become reality sooner than you think! Everyone is fascinated when they hear about it for the first time: we can use various technologies to produce fuels and renewable energies from captured CO₂. With the same technologies, we can also*



produce chemical building blocks with which it is possible to supply basically all chemical and plastics industries.

The nova conference will showcase the path-breaking developments. We hope you take part in the largest event on Carbon Capture and Utilisation (CCU) where more than 200 participants from leading industrial and academic players in CO₂ utilisation are expected to speed up developments in this up-and coming field.

Michael Carus
CEO, nova-Institute

QUICK FACTS

REGISTRATION

www.co2-chemistry.eu/registration

Contact

Dominik Vogt
nova-Institut GmbH

Phone +49 2233 4814 49
dominik.vogt@nova-institut.de
www.nova-institut.de

4th Conference on CO₂

Carbon Dioxide
as Feedstock for
Fuels, Chemistry
and Polymers

www.co2-chemistry.eu

Carbon Dioxide as Feedstock for Fuels, Chemistry and Polymers

29–30 September 2015, Haus der Technik, Essen (Germany)

Entrance Fee

Conference incl. catering

Two Days (29–30 September 2015): € 790
(incl. dinner buffet)

1st Day (29 September 2015): € 470
(incl. dinner buffet)

2nd Day (30 September 2015): € 420
plus 19% VAT.

**Undergraduate and PhD students can
attend the conference with a 50% discount.**

1st Day, 29 September 2015: Political framework & visions

- Policy & visions
- H₂ generation: prerequisite
for CO₂-economy

2nd Day, 30 September 2015: Chemicals & energy from CO₂

- CO₂ capture & purification
- Chemicals & polymers
- CO₂-based fuels

For the 4th year in a row, the nova-Institute will organize the conference “Carbon Dioxide as Feedstock for Fuels, Chemistry and Polymers” on 29 – 30 September 2015 in the “Haus der Technik” in Essen, Germany. CO₂ as chemical feedstock is a big challenge and chance for sustainable chemistry and has immense potential for the coming decade – much faster than expected! High on the European research agenda, scientists are very active in CCU research, especially in the fields of solar fuels (power-to-fuel, power-to-gas) – but also in CO₂-based chemicals and polymers. The implementation is only a stone’s throw from here and first pilot production plants are already installed.

More information at www.co2-chemistry.eu



Barbara Dommermuth

Programme

+49 (0) 22 33 / 48 14 - 56
barbara.dommermuth@nova-institut.de
@nova-institut.de



Dominik Vogt

Organisation


+49 (0) 22 33 / 48 14 - 49
dominik.vogt@nova-institut.de



nova-Institut GmbH

Chemiepark Knapsack
Industriestraße 300
50354 Hürth, Germany





EUROPEAN
BIOTECH
WEEK



12–18 October, 2015
Different locations across
Europe

Celebrating Biotech

EUROPEAN BIOTECH WEEK The aim of the annual European Biotech Week is to create dialogue around and share information on the benefits that biotech brings to society, in areas as diverse as health-care, agriculture, food, energy, water sanitation and biochemical processing.

The European Biotech Week is an opportunity for all supporters of biotechnology to develop events, activities and initiatives that improve dialogue and increase understanding of this amazing technology and the benefits it offers society. The 3rd edition will take place from 12th to 18th October 2015 across European countries.

Last year's edition of European Biotech Week featured more than 100 events

and manifold activities across Europe highlighting the benefits and applications of biotechnology: from high level policy debates, to award-winning industry events and company site visits, to workshops and career fairs for students, to social media competitions, theatrical performances, photo exhibitions, flash mobs and roving laboratories with hands-on biotech experiments, there was something for

anyone with a curious mind and an interest in finding out more about biotech.

EuropaBio and its national member associations and companies encourage all biotech supporters to organise initiatives and events, both large and small, right across Europe throughout the week. For more inspiration on activities running in 2015, find out what happened during the previous editions browsing the initiative's website at www.biotechweek.org.

By contacting EuropaBio, national biotech associations, companies, academic and government institutions, science museums and the media, as well as other biotech stakeholders can promote their activities on the dedicated website and have them featured in a post-event magazine available both online and as a printed version. Become part of the story of the European Biotech Week by contacting us. ■

Biotech counts

WELCOME NOTE *No other sector enhances quality of life, innovation, productivity and environmental protection like biotechnology, while also benefiting the economy. From new drugs that can fight epidemics and rare diseases, to industrial processes that use renew-*



able feedstocks instead of crude oil, to drought-resistant crops that allow farmers around the world to feed more people under ever-harsher climatic conditions, promoting and investing in biotech pays economic, social and environmental dividends. With European Biotech Week, EuropaBio aims to highlight and celebrate these achievements in Europe.

Nathalie Moll
Secretary General
EuropaBio

QUICK FACTS

HIGHLIGHTS

More than 200 events see:
www.biotechweek.org

CONTACT

Cosmin Popa
Communications Manager
EuropaBio

Phone +32 2 739 11 73
c.popa@europabio.org

EUROPEAN
BIOTECH
WEEK




12th - 18th October 2015

**Let's make the biotech
conversation count –
get involved in the 2015
European Biotech Week now!**

Promote your events and initiatives on
www.biotechweek.org

**Let's make the biotech conversation count –
get involved now!**

Find out more information on the website or follow us on
 [biotechweek](#)  [biotechweek](#)





14–16 October, 2015
Pacifico Yokohama,
Yokohama Japan

Partnering in Japan

BIOJAPAN 2015 BioJapan, the largest biotech event in Asia, will take place for the 17th time. BioJapan will cover almost all biotech fields and is expected to attract over 12,000 people as well as 750 exhibitors from 30 countries and regions, with an expected 8,000 one-to-one business partnering meetings over the three days.

BioJapan is Asia's premier event for the biotechnology industry. Each year, representatives from Japanese and global pharmaceutical and biotech companies gather in Yokohama to exchange information on the latest trends in the industry, to identify new business opportunities and to enter strategic relationships.

▶ QUICK FACTS

Visitor's Affiliation

- ▶ 34.4% Drug and Drug Discovery
- ▶ 14.0% University & Research Institutes
- ▶ 10.9% Research Tools/Contract Services

Networking Events

- ▶ 14 October: Evening Reception
- ▶ 15 October: Partnering Party

Contact

biojapan@ics-inc.co.jp
www.ics-expo.jp/biojapan

And the event continues to grow. It will feature more than 200 seminar sessions, including presentations by top researchers and business executives from Japan and overseas. BioJapan covers almost every key aspect of the biotech and Life Sciences industry. Session topics this year will include: Regenerative Medicine, Cell Therapy, Healthcare and the Internet of Things (IoT), Biomaterials and Functional Food. Strategies of global pharma companies, investment issues and best practices for biotech companies will also be discussed. Recent legislation changes to support innovation in the Japanese pharmaceutical and healthcare market are expected to have a big impact and will influence many of the discussions.

Dr Makoto Suematsu, President of the Japan Agency for Medical Research and Development (AMED) will give one of the keynote lectures. AMED was established this April, to promote integrated medical R&D from basic research to practical applications and to improve the environment for medical R&D in Japan. ■

Welcome to BioJapan 2015

GREETING As one of the major biotech markets, Japan has continued to be a key country for new business opportunities. BioJapan has been helping the growth of the market with its combination of exhibitions, partnering and seminars.



Once again, our Organising Committee has joined forces to provide attendees with a high quality conference, an enriching exhibition and efficient partnering. Japan has made biotechnology, regenerative and personalised medicine an important pillar of its growth strategy, and regulatory changes have created an overall climate that is more favourable than ever before. Not forgetting that Asia as a region holds great potential. This is why BioJapan is all set for three days of fruitful business opportunities. BioJapan's social events will certainly contribute in making participation at BioJapan 2015 a very special one.

We are very much looking forward to seeing old and new friends in Yokohama.

Michio Oishi

Chairman, BioJapan Organising Committee.



World Business Forum

BioJapan 2015

Y O K O H A M A

Pacifico Yokohama, JAPAN
October 14th(Wed.)-16th(Fri.), 2015

» PARTNERING


- 1,200 Participants
- 30 Countries
- 5,800 Meetings
- 2 Networking Parties

Partnering registration will open in mid-July!

Registration Fee: JPY 60,000 (approx. USD 500)

» EXHIBITION

- 500 Exhibitors
- 25 Countries
- 13,000 Visitors
- Global Pharma
- Biotech Ventures
- Research Institutes, University Labs
- Technology Licensing Organizations
- CRO / CMO etc.



» SEMINARS

From Market Overview to R&D Trend,
200 Organizer's Seminar and Exhibitors' Presentations

Call for Speakers for "Biotechnology Tomorrow" session!

<http://www.ics-expo.jp/biojapan/abstracts.html>



2015 Bioinnovation
International Summit

19–20 October, 2015
Gdansk Science & Technology
Park, Gdansk/Poland

Opportunities galore

BIOINNOVATION INTERNATIONAL SUMMIT Creating opportunities for innovation and cooperation is the main goal of the Bioinnovation International Summit. This year's key topics encompass the latest trends in the Life Sciences industry. In addition, founding as well as translation of research to market innovations will be discussed.

As in previous years, the Summit aspires to facilitate international cooperation between Business and Life Sciences, and support innovative young scientists in their search for investors and partners in the commercialisation of their ideas.

As a result of a cooperation between the Innovation Synergy Found, Pro Science Poland Ltd, Gdansk Science and Technology Park, together with the sup-

port from the City of Gdansk, Bioinnovation International Summit 2015 is going to be the next step towards broadening the horizon and increasing the involvement of its participants.

Bioinnovation Summit 2015 is for


- technology transfer experts – to exchange experience and discover new possibilities to translate projects from academic research to real life innovations,

- researchers – to explore possible commercialisation paths together with professional technology brokers and top-class industry representatives,
- industry representatives – to highlight their specific interests and needs in the field of new innovative technologies,
- investors – to explain the mechanism of financing innovative research with the industrial implementation potential, and
- young researchers – to present their ideas and discoveries during panel discussions and poster sessions.

Over the years, a number of world-class experts have honoured us with their presence and shared their experiences, insights and ideas. This year's conference is a place where scientists can meet the experts in commercialisation and where the industry can source new discoveries to be implemented in innovative products. ■

String of success

WELCOME NOTE Save the date for Bioinnovation International Summit 2015! During this event, technology transfer ex-



perts, scientists, investors and industry representatives from all around the world will gather at the Baltic port town of Gdansk to network and explore excellent

research results. All previous eight editions of the summit were a huge success, establishing a platform for international cooperation between business representatives and Life Sciences researchers.

The organiser's main goal is to create an environment for innovation and cooperation! Find out more at www.bioinnovation.pl and join us from 19 to 20 October in Gdansk!

Piotr Urbaszek
Project Manager
PRO-SCIENCE Poland Ltd

➤ QUICK FACTS

HIGHLIGHTS

Connecting the science and business environments; Presenting opportunities for innovative scientists; Introducing world-class experts; Illustrating the Life Sciences industry perspective; Envisioning founding possibilities

CONTACT

www.bioinnovation.pl
Phone: +48 881 60 9000

2015 Bioinnovation International Summit

GATHERING TECHNOLOGY TRANSFER EXPERTS FROM ALL OVER THE WORLD,
INNOVATIVE IDEAS, FOUNDERS AND INDUSTRY FOR THE LIFE SCIENCE

POSTER
SESSION

TECHNOLOGY
TRANSFER
EXPERTS



INDUSTRY
PERSPECTIVES

FUNDING
POSSIBILITIES



OCTOBER 19-20, 2015
Gdansk, Poland



INNOVATIVE
IDEAS

TECHNOLOGY
TRANSFER


LEARN MORE AND REGISTER NOW AT WWW.BIOINNOVATION.PL

Organizers



GDANSK
www.gdansk.pl





2-4 November, 2015
International Congress Center
(ICM), Munich, Germany

Tangible excitement

BIO-EUROPE The 21st edition of BIO-Europe international partnering conference will take place in Munich, Germany. The event brings together C-suite decision makers from international life science companies in search of in-licensing and investment opportunities that will result in the deals that ultimately propel the drug development industry.

Munich, Germany will host what the international Life Science industry considers to be its most productive partnering event: BIO-Europe 2015. The main draw for executive-level decision makers from pharma, biotech, finance and service partners is what is known in the industry as “partnering.” These are one-to-one, private business development and discovery meetings that are the backbone of the event, and which have led to some of

the biggest M&A and collaboration deals over the past two decades.

Now in its 21st edition, BIO-Europe is also highly regarded for the variety of presenting companies, ranging from academic innovators to mid-size pharma and biotech, who come to the event with the goal of securing development and commercialisation partners. If the partnering can be considered the engine, the presenting companies are the fuel that

drives the event. BIO-Europe also features a diverse list of industry leaders speaking on panels and workshops.

Leading pharmaceutical companies sponsoring the event send teams of scouts to BIO-Europe to engage with new and innovative products, ideas and companies. Past sponsors include big names in pharma such as AbbVie, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Johnson & Johnson, Lilly, Merck, Merck Serono, Novartis, Novo Nordisk, Pfizer, Roche, Sanofi, Takeda and many others.

The 2014 event boasted an all-time record of 17,902 scheduled one-to-one meetings with 4,032 licensing opportunities posted from among 1,772 companies that attended. “There is tangible excitement around the arrival of BIO-Europe also this year,” said Anna Chrisman, Group Managing Director of EBD Group. “It is partnering that drives the industry’s growing demand for transformational breakthroughs.” ■

Biotech Hotbed

GREETING *BIO-Europe 2015 is the engine that continues to drive partnering in the Life Sciences, and is a key strategy for global biotech, pharma and investors who attend in search of new collaboration partners and deal opportunities. Munich is a favourite central Eu-*



ropean location and a hotbed of drug development activity. The event is expected to draw a high calibre of companies, not only from Munich and Bavaria, but from across the globe to fuel the insatiable drug development industry with their innovative technologies, therapies and solutions.

See you in Munich this November!

Anna Chrisman
 EBD Group
 Group Managing Director

QUICK FACTS

REGISTRATION

Early registration runs until 31 August, 2015. Companies with three full-paying delegates will receive one complimentary ticket for the fourth attendee from that company. Online registration will close on 30 October.

MORE INFORMATION

www.ebdgroup.com/bioeurope
 Phone: +49 89 2388 7560

21ST ANNUAL INTERNATIONAL PARTNERING CONFERENCE

BIO-EUROPE® 2015

NOVEMBER 2-4, 2015 // MUNICH, GERMANY



Building value through partnerships

BIO-Europe® is Europe's largest partnering conference serving the global biotechnology industry. The conference annually attracts international leaders from biotech, pharma and finance along with the most promising startups and emerging companies. It is the "must attend" event for getting business done in the biotech industry.

Important deadlines:

July 31, 2015 - Apply to present deadline

August 31, 2015 - Early registration deadline

September 21, 2015 - Online Partnering opens

Please use registration code: **DE021_BEU15_EBN**


Produced by

EBD
GROUP

In collaboration with

Bio Biotechnology
Industry
Organization

Find out more: www.ebdgroup.com/bioeurope



DIA DEVELOP
INNOVATE
ADVANCE

4–5 November, 2015
De Vere Venues, Canary Wharf
London, UK

Staying on top

DIA EUROPEAN BIOSIMILARS CONFERENCE Ten years after the introduction of a regulatory pathway for biosimilars in the EU, DIA is arranging its third annual EU conference on this ever-evolving scientific and regulatory topic to keep all relevant stakeholders up to date.

When it comes to biosimilars, Europe is the global spearhead. And the sector has come a long way since the first biosimilars went through regulatory approval ten years ago. Meanwhile, the number of approved biosimilars is close to twenty products, and the most recent approval of the first biosimilar monoclonal antibody has made clear the potential impact of biosimilars on market dynamics. The continuing development in the area of biosimilars makes this an-

nual conference an important event to attend for all stakeholders.

This year's conference will provide an update on the current regulatory situation in the EU, but also look beyond European borders and put biosimilars into a global perspective. As in previous years, the conference will provide an update on the market access situation in the EU and address a number of current hot topics, among them patients' and prescribers' experiences and attitude towards the use of biosimilars.

QUICK FACTS

Highlights

- Regulatory status, market access
- Naming of biosimilars
- Pharmacovigilance issues
- Market experience

Contact:

DIA Europe, Middle East & Africa
DIAEurope@diaeurope.org
Phone: +41 61 225 51 51
www.DIAglobal.org

Approved, but not subscribed?

Despite the relatively high number of biosimilars approved in the EU, market access varies significantly. One explanation is clearly the physicians' and patients' perception of biosimilars and their willingness to prescribe or be treated with them. The 2015 DIA EU biosimilar conference attempts to explore this important topic further by involving representatives from all relevant stakeholder groups as speakers and panellists for discussion. ■

Biosimilars: An evolving story

GREETING *This year's DIA EU biosimilar conference will be the third of its kind welcoming participants from previous years and especially those of you who are new to this topic. Having had the privilege to chair the two previous conferences, I can promise all participants a scientifically interesting and thought-provoking programme as well as a great opportunity to connect with new and old colleagues within the global field of biosimilars. The organising committee has strived to make a programme that on one hand will provide the audience with the next chapter in the continuously evolving story of biosimilars in the EU and at the same time, open up new doors to the rest of the world under the theme "A European View on Biosimilars with a Global Outlook". I am looking forward to welcoming all of you at the conference in November in London, UK.*



Steffen Thistrup

Programme Chair
Director and Advisory Board Member,
NDA Advisory Services Ltd, UK;
Previous CHMP-member and Head of
Licensing, Danish Health and Medicines Authority



Register
now

Biosimilars Conference – A European View on Biosimilars with a Global Outlook

4-5 November 2015, London

DIAGlobal.org/Biosimilars2015

This 2-day conference will provide an update on the current status for biosimilars in the EU and internationally, focusing on both regulatory and scientific challenges as well as market access and experiences. The conference will include the approach of patients' and physicians' to the use of biosimilars and discuss the adoption of current treatment guidelines in the EU. The conference will consist of plenary lectures followed by interactive panel discussions providing participants an opportunity to bring forward their own experience and share their thoughts and ideas.

Key Topics

- Current regulatory status of biosimilars in the EU
- International development of biosimilars
- Naming of biologicals including biosimilars
- Pharmacovigilance issues related to biosimilars – EU and globally
- Market experience with biosimilars including market access and pricing
- Patient and physicians approach to the use of biosimilars

DEVELOP.
INNOVATE. ADVANCE.

DIA volunteers, members, and staff provide a comprehensive catalogue of conferences, workshops, training courses, scientific publications and educational materials, throughout the year, all around the world.

DIA DEVELOP
INNOVATE
ADVANCE

DIA Europe, Middle East & Africa
Küchengasse 16
4051 Basel, Switzerland

Basel, Switzerland | Beijing, China | Horsham, PA, USA | Mumbai, India | Tokyo, Japan

Discover new opportunities at DIAGlobal.org



10–11 November, 2015
Swissôtel Congress Centrum
Düsseldorf/Neuss, Germany

Target lab compliance

PHARMALAB For the 3rd year running, PharmaLab calls upon the latest regulatory and scientific developments in all laboratory areas of the pharma industry. The analytical, bioanalytical and microbiology conferences are accompanied by an exhibition, in which suppliers of lab materials and equipment as well as contract laboratories present their current products and services.

Currently, the European Pharmacopoeia chapters on monocyte activation tests, pyrogens as well as guidelines for using the test for bacterial endotoxins are under revision. Naturally, a conference will pick up and discuss these developments. Special attention is paid to the masking of endotoxins and low endotoxin recovery – and the current strategies to deal with this effect.

Pharmeuropa recently issued the draft of the revised Ph.Eur. Chapter 5.1.1 on “Modern Microbiological Methods”. New at PharmaLab is therefore the Rapid Microbiological Methods Conference, providing first-hand information on the state of the revision and the revised requirements. Another challenge in the field of microbiological testing is the evidence of so-called adventitious agents such as mycoplasma and viruses. A fur-

ther “newcomer” will hence cover the authorities’ requirements on the one hand, and the currently available detection methods on the other.

A session on the validation of bioanalytical methods will concentrate on the statistical analyses that are necessary for the calculation of bioactivity. “Laboratory Informatics” will this year centre on the integrity of the data produced in the lab as well as on laboratory data systems and how they can be implemented in today’s QC and R&D environments.

The most recent regulatory developments and compliance aspects will be the focus of the eponymous conference “cGMP compliance trends in analytical quality control”.

In addition to the above mentioned conferences, German-speaking lecturers will provide comprehensive updates on bioanalytics, leachables and extractables, lab optimisation and pharmaceutical analytics in so-called national sessions. ■

Forum for lab professionals

GREETING *Laboratory compliance is a vast field providing plenty of subjects we could have chosen for PharmaLab 2015. We are certain we have picked those subjects that are most up-to-date and highly relevant*



in your day-to-day business. Together with the exhibition specifically designed for all suppliers in the laboratory environment, PharmaLab 2015 will once again provide you with a valuable learning and networking experience.



Axel H. Schroeder (left) & Dr Günter Brendelberger
 Concept Heidelberg
 Operations Directors

QUICK FACTS

CONTACT & REGISTRATION

www.pharmalab-congress.com

HIGHLIGHTS

10 November Jack Levin: The LAL Test for Bacterial Endotoxins – Discovery, Development and Applications

11 November Frans Maris: Regulations on Heavy Metals – Update on the status of USP, FDA and ICH Guidelines and path forward at MSD.

PharmaLab 2015

Bioanalytics, Analytics, und Microbiology
- Congress & Exhibition -

Swissôtel Düsseldorf/Neuss
10/11 November 2015

www.pharmalab-congress.com

Scan code to learn more



No matter whether bioassays, bioanalytics, stability testing or the validation of these methods, PharmaLab provides the ideal forum to discuss current trends, developments and applications in the pharmaceutical lab. And for you as a solutions provider the PharmaLab exhibition is thus the right platform to present your latest technologies and services for the modern lab.

Create your own programme out of the following conferences:

Bioanalytics

Validation of Bioassays
Bioassays und Stabilitätsprüfung*

Analytics

Laboratory Informatics
Analytical Compliance Trends
Laboroptimierung*
Leachables & Extractables*
Aktuelle Praxisbeispiele im Labor*

Microbiology

Endotoxin and Pyrogen Testing
Rapid Microbiological Methods
Adventitious Agents

Media Partner:



*German speaking Conferences

CONCEPT
HEIDELBERG

Pharmaceutical Quality
Training. Conferences. Services.



3rd International mRNA Health Conference

11–12 November, 2015
Hilton Hotel
Berlin, Germany

Hotspot mRNA

MRNA CONFERENCE Up to 400 innovators, scientists, and academia and pharma delegates are expected to attend the 3rd International mRNA Health Conference, a key date for everyone who is working with mRNA for medical purposes or seeking messenger RNA as a novel tool to express proteins directly in situ.

The two-day conference provides a meeting point for international experts to discuss the enormous potential of mRNA for many therapeutic indications and prophylactic use. Participants can count on two days of exciting talks and discussions, and build personal connections. Around 30 speakers will present on science, preclinical and clinical research, manufacturing, delivery, and regulatory aspects. A poster session

will provide research groups the opportunity to show their data to the audience. mRNA offers tremendous near term potential for many therapeutic applications. The momentum of research and development of mRNA-based therapeutics and vaccines is accelerating from year to year. Some of the leading companies have already acquired a large number of investments, and are already conducting extensive collaborations with Big Pharma.

The first ever clinical studies in the field of mRNA are already running and more are to come – treatment options ranging from cancer, infectious diseases to cardiovascular diseases are becoming more and more feasible. These trials will yield important results as soon as next month and – hopefully – the first mRNA-based drug will be available for patients within the next decade.

Everyone in the ‘mRNA community’ is venturing into new and unknown territory. There is still room to set up new benchmarks in the field. To build this industry, scientific and business collaborations between key players in the mRNA field, as well as with pharmaceutical and biotech partners, suppliers, and academic and clinical centres are essential. After successful conferences in the last two years – the first in 2013 in Tübingen, Germany, and in 2014 in Cambridge, MA, USA – the conference will return this year to Germany. ■

Taking part

WELCOME NOTE *It's my special pleasure to welcome you to the 3rd International mRNA Health Conference. Continuous research has led to amazing progress in this exciting field in the last few years. Our community has overcome many of mRNA's limitations, and today more and more*



dedicated scientists around the world are developing drugs based on this highly potent biomolecule. mRNA has been transformed into an entirely new class of therapeutic molecules with wide-ranging applications. This year's conference will provide insights into the latest clinical data. We are looking forward to two inspiring and informative conference days, and to providing a warm welcome to many new colleagues in the mRNA field!

Ingmar Hoerr
CEO and Cofounder of CureVac

QUICK FACTS

VENUE

HILTON Hotel
Mohrenstrasse 30

CONTACT

Verena Lauterbach
Manager Communications, CureVac

Phone +49 7071 920 53 756
verena.lauterbach@curevac.com
www.mrna-conference.com

SAVE THE DATE

3rd International **mRNA** Health Conference

First special forum for therapeutic **mRNA**



Join us for the 3rd International **mRNA** Health Conference

November 11–12, 2015

Berlin, Germany

HILTON BERLIN

mRNA is in substantial progress to become a new class of drugs. It may transform the treatment of many human diseases and disorders.

Meet innovators, scientists, academia and pharma delegates and get the latest news about this groundbreaking technology.

More information on the conference and registration can be found under

www.mrna-conference.com

→ Early-bird registration until September 29th

Contact

Verena Lauterbach, Verena.Lauterbach@curevac.com

Phone: +49 (0)70 71 92 05 37 56



euroPLX  59 Athens

23–24 November, 2015
Hotel Grande Bretagne
Athens, Greece

Golden 20s kick-off

EUROPLX 59 ATHENS 2015 is the 20th anniversary year of euroPLX Pharma Partnering Conferences. With attendees from almost 1,500 companies headquartered in 80 countries in total, geographically, euroPLX has been global from the onset. And once again, business development executives from 35 to 40 countries are expected at euroPLX 59 this autumn.

What a change there has been since the first euroPLX Partnering Conference in 1995, and the 59th that will be held from 23 to 24 November, 2015, in Athens, Greece! Back then, barely anyone had an email address to communicate with and the entire pre-conference partnering process had to be done by fax. Twenty years later, all of this is done online and on smart phones, using the latest technology and one of

the most efficient scheduling systems for one-on-one meetings around. Each euroPLX Partnering Conference is preceded with several thousand platform-supported email communications between the delegates whose information exchange determines the outcome of their negotiations at the conference.

Today, more than 10,000 pre-arranged business negotiations take place at euroPLX events per year, which

renders them the place to be for many types of business agreements in the global pharmaceutical and biotechnology industries. Although late development stage product candidates are an important matter of interest, the majority of discussions are about approved products: chemical drugs, biologics, biosimilars, medical devices, and food supplements. Prescription drugs for practitioners and hospitals have predominated so far, but OTC products are rapidly gaining ground. All in all, negotiations centre around topics like codevelopment, marketing, distribution, contract manufacture, mergers and acquisitions. Depending on the topics of submitted collaboration interests, the "Dynamic Partnering Focus" of euroPLX 59 Athens will evolve within the weeks to come. After a relevant number of entries have been received it will be displayed on the event's website. ■

One-on-one only

GREETING With almost 60 successful events since 1995, all attended by pharma and biotech business development executives from an average of 35 countries – the hitherto unheard-of concept of euroPLX Conferences has turned out to be a success. One-on-one business meet-



ings only, no lectures, no company presentations – in the early years, marketing this concept was not easy. But by now, executives have learnt that this concept is quite profitable. Each euroPLX Conference delivers 23 to 29 pre-scheduled and well-prepared meetings per company, an unrivaled benchmark for a two-day partnering conference. So if you have a business to do, join us at the last event of our anniversary year in Athens.

Dr Norbert Rau
Coinitiator of euroPLX

QUICK FACTS

DELEGATES

CEOs, owners, vice presidents, directors, and BD&L managers from a maximum of 150 companies

TIMELINE

Regular registration runs until 5 November. Late Registration (reduced options) is possible until 16 November.

www.europlx.com

Since Twenty Years

euroPLX has been the world's most often held partnering conference for the pharma and biotech industries.

Because of results delivered.

Second to none.
Don't miss the next two.

Seeking and offering business opportunities in patented and generic (incl. biosimilars), prescription and OTC drugs, medical devices, and nutraceuticals - development, licensing, marketing, promotion, and distribution...

Each euroPLX Conference's actual collaboration interests are summarised and displayed on www.europlx.com as an hourly updated *Dynamic Partnering Focus*, as soon as sufficient data are submitted by registrants.

Register online: www.europlx.com

Productive Partnering for Pharma Deals



Langer Anger 75
69115 Heidelberg, Germany
ph. ++49 (6221) 4262960
meetyou@europlx.com



Since 1995. Made in
Europe for the World.

Year-Round Business Development